Advertisement
Advertisement

CADL

CADL logo

Candel Therapeutics, Inc. Common Stock

5.82
USD
Sponsored
-0.11
-1.87%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

5.79

-0.02
-0.41%

CADL Earnings Reports

Positive Surprise Ratio

CADL beat 8 of 15 last estimates.

53%

Next Report

Date of Next Report
Mar 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.25
Implied change from Q3 25 (Revenue/ EPS)
--
/
+19.05%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-37.50%

Candel Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, CADL reported earnings of -0.21 USD per share (EPS) for Q3 25, missing the estimate of -0.18 USD, resulting in a -11.23% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an increase of 19.05% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Candel Therapeutics, Inc. Common Stock reported EPS of -$0.21, missing estimates by -11.23%, and revenue of $0.00, 0% as expectations.
The stock price moved down -6.3%, changed from $4.92 before the earnings release to $4.61 the day after.
The next earning report is scheduled for Mar 23, 2026.
Based on 9 analysts, Candel Therapeutics, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement